Full Press Release Details
CAMBRIDGE, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present third quarter 2018 results and corporate developments in a conference call on Oct. 31, 2018 at 8 a.m. ET.
The investor presentation may be downloaded starting at 8 a.m. ET from the Events and Presentations page of the Investor Relations section of Intellia’s website at intelliatx.com.
U.S. callers should dial 866-548-4713 and use conference ID# 5893807, approximately five minutes before the call.
International callers should click here to access dial-in information and use conference ID# 5893807, approximately five minutes before the call.
A replay of the call will be available on Intellia’s website, beginning on Oct. 31, 2018 at 12 p.m. ET.
About Intellia Therapeutics
Vice President, Investor Relations
Jennifer Mound Smoter